The African swine fever vaccine developed by Hubei Province has been the first to obtain clinical approval.

On July 31st, Guoyao Group Animal Health Co., Ltd. received good news: the company was issued a clinical trial approval for the African swine fever vaccine by the Ministry of Agriculture and Rural Affairs, becoming the first domestic enterprise to receive such approval. Guoyao Animal Health has been closely following the trends of animal diseases at home and abroad, focusing on the research and development of vaccines for diseases like porcine blue ear disease and porcine circovirus. They have previously developed the world's first genetically engineered live vaccine for porcine blue ear disease. In 2021, the company ventured into the technological "no man's land" by establishing a team for the development of the African swine fever vaccine. Over the past four years, the team has conducted research on antigen production processes, pilot processes, establishment of testing methods for semi-finished and finished products, and research on vaccine stability, completing laboratory trial production research on multiple batches of African swine fever vaccines and safety studies on vaccine finished products.